# Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

Study · id `cardio:ct-nct01032395` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01032395](<https://clinicaltrials.gov/study/NCT01032395>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01032395

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 342 participants.

## Technical summary

Registry record NCT01032395. Randomized; no masking; primary purpose prevention. Start 2010-03 (registry gives no type); primary completion 2011-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 342 participants (enrolled count; ClinicalTrials.gov record NCT01032395, source copy `cardio:ctgov-nct01032395-2013-06-14`, retrieved 2026-10-26)
- Start date: 2010-03 (registry gives no type) (ClinicalTrials.gov record NCT01032395, source copy `cardio:ctgov-nct01032395-2013-06-14`, retrieved 2026-10-26)
- Primary completion: 2011-10 (actual) (ClinicalTrials.gov record NCT01032395, source copy `cardio:ctgov-nct01032395-2013-06-14`, retrieved 2026-10-26)
- Completion: 2012-08 (actual) (ClinicalTrials.gov record NCT01032395, source copy `cardio:ctgov-nct01032395-2013-06-14`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT01032395, source copy `cardio:ctgov-nct01032395-2013-06-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01032395-2013-06-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus
- Condition: H1N1 Influenza Virus
- Condition: Chronic Pulmonary Disease
- Condition: Chronic Heart Disease
- Condition: Diabetes Mellitus
- Intervention (Biological): Focetria®
- Intervention (Biological): Fluad®
- Intervention (Biological): Begrivac®
- Lead sponsor: Chiltern Pesquisa Clinica Ltda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 6945e700ce658f296fd4863d46628d0b1875fd0a38f2412e19c4d7a73ca5e009
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
